MOLOGEN AG
MOLOGEN at SITC 2015: Preliminary data from IMPALA trial confirm mode of action of MGN1703 (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Conference PRESS RELEASE N 18 / 2015 of 11/09/2015 MOLOGEN at SITC 2015: Preliminary data from IMPALA trial confirm mode of action of MGN1703 Berlin, 9 November 2015 – The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented data on the immunotherapy MGN1703 at 2015 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland/US (November 4 – 8, 2015). The exploratory immunological data from a preliminary analysis of the IMPALA pivotal study in patients with colorectal cancer confirm the mode of action of MGN1703, the activation of the immune system. Promising data from the previous phase II IMPACT study in colorectal cancer suggest that the overall survival of a subgroup of patients who responded to induction therapy could be increased. Based on these findings, the pivotal IMPALA study aims to prove that a switch maintenance treatment with an active immunotherapy could increase the overall survival of patients who respond to prior induction therapy. The activation of the immune system as seen in the IMPACT trial is now confirmed by the preliminary analyses of immunological data of the phase III IMPALA trial. The identified activation profile of immune cells like monocytes, natural killer T cells (NKT), natural killer cells and T cells prove the mode of action of the TLR9 agonist MGN1703. Further translational data will be generated and correlated to the clinical outcome which may help identifying useful biomarkers. These biomarkers can be used for defining subgroups of patients who benefit the most from MGN1703 therapy. Recruitment of the IMPALA study started in September 2014 and is expected to enroll 540 patients in 8 European countries by the second half of 2016. Further to the IMPALA trial in colorectal cancer, MGN1703 is being investigated for first-line maintenance treatment of extensive-stage small cell lung cancer, a serious cancer disease with high unmet medical need. IMPULSE, an international randomized controlled trial, completed just recently the enrolment of 100 patients. Abstract details: For more information on the Society for Immunotherapy of Cancer Conference (SITC 2015) please visit the website http://www.sitcancer.org. About IMPALA Approximately 540 patients from more than 100 European centers, including the five major pharma markets, will participate in the study. IMPALA started to treat the first patients in mid-September 2014. For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov. MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=VMARXLOADI Document title: MOLOGEN at SITC 2015: Preliminary data from IMPALA trial confirm mode of action of MGN1703 2015-11-09 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |
410223 2015-11-09 |